Find Drugs for Infections and Infectious Diseases in Phase III Clinical Development in UNITED KINGDOM

Lead Product(s): Ridinilazole

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Eurofarma Laboratorios SA

Deal Size: $3.8 million Upfront Cash: Undisclosed

Deal Type: Collaboration February 06, 2020

Details:

The milestone payment was initiated by Summit achieving its initial patient enrolment target at trial sites in Latin America in the Phase 3 clinical trials of ridinilazole for C. difficile infection.

Lead Product(s): Ridinilazole

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Biomedical Advanced Research and Development Authority

Deal Size: $72.5 million Upfront Cash: Undisclosed

Deal Type: Funding January 23, 2020

Details:

The additional funding is being provided to support a new clinical trial in adolescent patients and brings the total value of the award to up to $72.5 million.

Lead Product(s): Fostemsavir

Therapeutic Area: Infections and Infectious Diseases

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

This application seeks approval of fostemsavir, used in combination with other antiretrovirals, for the treatment of adults with multidrug-resistant HIV-1 infection.